Bain leads big $70M round as Aptinyx plunges deeper into NMDA work
Two years after Aptinyx spun out of Naurex in the wake of Allergan’s $560 million buyout, the biotech is much further along in the pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
